Various Arg-Gly-Asp (RGD) derivatives have been labeled with various radioisotopes for targeting αvβ3 integrin, which is expressed during angiogenesis in tumor. In this study, 2-(4′-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA-SCN) and its c(RGDyK) conjugate (NOTA-SCN-c(RGDyK)) were labeled with 177Lu, which is a near ideal radionuclide for treating tumors because it emits therapeutic beta particles and gamma rays for monitoring. 177Lu (250 MBq) was labeled with 50 μg NOTA-SCN-c(RGDyK) quantitatively. The specific activity of 177Lu-NOTA-SCN-c(RGDyK) was 1.44 × 105 Ci/mol. Biodistribution study was performed in Balb/c mice xenografted with CT-26 (mouse colon cancer) cells. The highest uptake was found in kidneys (7.56% ± 0.71% ID/g at 1 hour), and tumor uptake was 1.70% ± 0.33% ID/g at 1 hour postinjection. Moderate tumor-to-blood (2.36 ± 0.29) and tumor-to-muscle (2.06 ± 0.40) ratios were observed. This study shows that 177Lu-NOTA-SCN-c(RGDyK) is a potential therapeutic agent for angiogenic tumors, but special care is required to prevent kidney toxicity.
Get full access to this article
View all access options for this article.
References
1.
CarmelietP, JainRK. Angiogenesis in cancer and other diseases. Nature, 2000; 407:249.
2.
RuoslahtiE, PierschbacherMD. New perspectives in cell adhesion: RGD and integrins. Science, 1987; 238:491.
BrooksPC, ClarkRA, ChereshDA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994; 264:569.
6.
AllmanR, CowburnP, MasonM. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells. Eur J Cancer, 2000; 36:410.
7.
BrooksPC, StrombladS, KlemkeRet al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 1995; 96:1815.
8.
HaubnerR, WesterHJ, ReuningUet al. Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med, 1999; 40:1061.
9.
HaubnerR. Alphavbeta3-integrin imaging: A new approach to characterise angiogenesis?Eur J Nucl Med Mol Imaging, 2006; 33,Suppl1:54.
10.
JanssenM, OyenWJ, MassugerLFet al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm, 2002; 17:641.
JanssenML, OyenWJ, DijkgraafIet al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res, 2002; 62:6146.
13.
ZhangX, XiongZ, WuYet al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med, 2006; 47:113.
14.
MoonEH, LimST, JeongYJet al. Efficacy of I-123/I-131 metaiodobenzylguanidine scan as a single initial diagnostic modality in pheochromocytoma: Comparison with biochemical test and anatomic imaging. Nucl Med Mol Imaging, 2009; 43:436.
15.
KimKH, KimSM, SeoYD. A discrepancy between 131I-metaiodobenzylguanidine (131I-MIBG) scintigraphy and 18F-FDG PET/CT after 131I-MIBG therapy in a patient with recurred malignant pheochromocytoma. Nucl Med Mol Imaging, 2009; 43:582.
16.
YoshimotoM, OgawaK, WashiyamaKet al. Alpha(v)beta(3) integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int J Cancer, 2008; 123:709.
17.
ChakrabortyS, DasT, SarmaHDet al. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol, 2008; 35:589.
18.
ChakrabortyS, DasT, SarmaHDet al. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot, 2008; 66:1196.
19.
JeongJM, HongMK, ChangYSet al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med, 2008; 49:830.
20.
StuderM, MearesCF. Synthesis of novel 1,4,7-triazacyclononane-N,N',N''-triacetic acid derivatives suitable for protein labeling. Bioconjug Chem, 1992; 3:337.
21.
McMurryTJ, BrechbielM, WuCet al. Synthesis of 2-(p-thiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: Application of the 4-methoxy-2,3,6-trimethylbenzenesulfonamide protecting group in the synthesis of macrocyclic polyamines. Bioconjug Chem, 1993; 4:236.
22.
JeongJM, ChungJK. Therapy with 188Re-labeled radiopharmaceuticals: An overview of promising results from initial clinical trials. Cancer Biother Radiopharm, 2003; 18:707.
23.
PillaiMR, ChakrabortyS, DasTet al. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot, 2003; 59:109.
24.
JeongJM, KnappFFJr. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Semin Nucl Med, 2008; 38:S19.
25.
ChakravartyR, PandeyU, ManolkarRBet al. Development of an electrochemical 90Sr-90Y generator for separation of 90Y suitable for targeted therapy. Nucl Med Biol, 2008; 35:245.
26.
CacherisWP, NickleSK, SherryAD. Thermodynamic study of lanthanide complexes of 1,4,7-triazacyclononane-N,N',N''-triacetic acid and 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid. Inorg Chem, 1987; 26:958.
27.
JeongJM, KimYJ, LeeYSet al. Radiolabeling of NOTA and DOTA with positron emitting 68Ga and investigation of in vitro properties. Nucl Med Mol Imaging, 2009; 43:330.
